Mixed Hyperlipidemia
Links shared publicly online about this topic
Livalo available for primary hyperlipidemia and mixed dyslipidemia - ONA
oncologynurseadvisor.com — “Livalo (pitavastatin tablets) has been made available by Kowa for use in adults for the treatment of primary hyperlipidemia and mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 21, 2010 at 10:37 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Livalo available for primary hyperlipidemia and mixed dyslipidemia http://goo.gl/fb/WzQrv
Livalo available for primary hyperlipidemia and mixed dyslipidemia - MPR
empr.com — “Livalo (pitavastatin tablets) has been made available by Kowa for use in adults for the treatment of primary hyperlipidemia and mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).” View full resource at empr.com
Most Recently Shared on June 21, 2010 at 8:56 pm By:
MPR News: Livalo available for primary hyperlipidemia and mixed dyslipidemia: Livalo (pitavastatin tablets) has be... http://bit.ly/asp2kq
Family Medicine Article | Hyperlipidemia
mdlinx.com — “Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia” View full resource at mdlinx.com
Most Recently Shared on September 7, 2011 at 2:07 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibi... http://t.co/2D5TPkn #FamPractice
Endocrinology Article | Hyperlipidemia
mdlinx.com — “Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia” View full resource at mdlinx.com
Most Recently Shared on September 7, 2011 at 4:10 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor ana... http://t.co/m8u1aum #endo
Endocrinology News & Articles - MDLinx - Hyperlipidemias on #MDlinx
mdlinx.com — “Endocrinology News & Articles - MDLinx - Hyperlipidemias on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on September 3, 2010 at 5:49 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controll... http://bit.ly/cQNoEY #endo
Nursing News & Articles - MDLinx - Hyperlipidemias on #MDlinx
mdlinx.com — “Nursing News & Articles - MDLinx - Hyperlipidemias on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on September 4, 2010 at 11:04 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Contr... http://bit.ly/bIkrnO #Nursing
Family Medicine News & Articles - MDLinx - Hyperlipidemias on #MDlinx
mdlinx.com — “Family Medicine News & Articles - MDLinx - Hyperlipidemias on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on September 7, 2010 at 6:24 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Co... http://bit.ly/cTZ8PB #GM #mdlinx
Cardiology News & Articles - MDLinx - Hyperlipidemias on #MDlinx
mdlinx.com — “Cardiology News & Articles - MDLinx - Hyperlipidemias on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on September 7, 2010 at 8:22 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Co... http://bit.ly/b3J8Hj #cardiology
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
drugs.com — “Zyprexa (olanzapine) is used to treat Schizophrenia and Bipolar I Disorder in Adolescents. Includes Zyprexa side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on December 7, 2009 at 11:54 pm By:
FDA Approves Lilly's Zyprexa for Two Adolescent Indications - http://bit.ly/7VAdnv
FDA Approves Lilly's Zyprexa For Two Adolescent Indications
medicalnewstoday.com — “The U.S. Food and Drug Administration (FDA) approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I” View full resource at medicalnewstoday.com
Most Recently Shared on December 5, 2009 at 12:19 pm By:
FDA Approves Lilly's Zyprexa For Two Adolescent Indications: The U.S. Food and Drug Administration (FDA) approv.. http://bit.ly/57Yb0c
LIVALO - New Product Releases - MPR
empr.com — “Adjunct to diet: To reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.” View full resource at empr.com
Most Recently Shared on June 25, 2010 at 2:54 pm By:
MPR News: LIVALO: Pitavastatin 1mg, 2mg, 4mg; tabs. http://bit.ly/alJZwr
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
